Skip to main content
SpringerLink
Log in
Book cover

Oxidative Stress and Neuroprotection pp 157–161Cite as

The use of rasagiline in Parkinson’s disease

  • Chapter

Part of the book series: Journal of Neural Transmission. Supplementa ((NEURALTRANS,volume 71))

Summary

Rasagiline is a novel, potent, irreversible inhibitor of monoamine oxidative B developed for the symptomatic treatment of Parkinson’s disease. The drug has shown efficacy in improving motor features in both early and advanced Parkinson’s disease patients. The drug appears to be well tolerated and its once daily fixed dose formulation should make for excellent compliance. Rasagiline has also demonstrated important neuroprotective properties in both in vitro and in vivo laboratory studies. A provisional study of neuroprotection in a delayed start clinical trial of early PD patients has also suggested that this benefit may be translated to the clinic. Additional clinical trials are underway to confirm this.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J (1997) Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49: 393–399

    PubMed  CAS  Google Scholar 

  • Bar Am O, Amit T, Youdim M (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355: 169–172

    Article  PubMed  CAS  Google Scholar 

  • Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G (2004) Neuroprotective effects of rasagiline in a rodent model of Parkinson’s disease. Exp Neurol 187: 455–459

    Article  PubMed  CAS  Google Scholar 

  • Bonneh-Barkay D, Ziv N, Finberg JPM (2005) Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharm 48: 406–416

    Article  CAS  Google Scholar 

  • Chen J, Swope D (2005) Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson’s disease. J Clin Pharm 45: 878–894

    Article  CAS  Google Scholar 

  • Finberg JP, Takeshima T, Johnston JM, Commissiong JW (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase-B inhibitor. Neuroreport 9: 703–707

    Article  PubMed  CAS  Google Scholar 

  • Goggi J, Theofilipoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF (2000) The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurons in culture. Neuroreport 11: 3937–3941

    Article  PubMed  CAS  Google Scholar 

  • Kamada T, Chow T, Hiroi T (2002) Metabolism of selegiline hydrochloride, a selective monoamine B-type inhibitor, in human liver microsomes. Drug Metab Pharmacokinet 17: 199–206

    Article  PubMed  CAS  Google Scholar 

  • Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49: 162–168

    PubMed  CAS  Google Scholar 

  • Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 51: 1057–1062

    CAS  Google Scholar 

  • Mandel S, Weinreb O, Amit T, Youdim MBH (2005) Mechanism of neuroprotection of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 48: 379–387

    Article  PubMed  CAS  Google Scholar 

  • Maruyama W, Weinstock M, Youdim MBH, Nagai M, Naoi M (2003) Antiapoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholineste-rasemonoamine oxidase inhibitor. Neurosci Lett 341: 233–236

    Article  PubMed  CAS  Google Scholar 

  • Maruyama W, Nitta A, Shamoto-Nagai M (2004) N-propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κ B transcription factor. Neurochem Intl 44: 393–400

    Article  CAS  Google Scholar 

  • Naoi M, Maruyama W (2001) Future of neuroprotection in Parkinson’s disease. Parkinsonism Relat Disord 8: 139–145

    Article  PubMed  CAS  Google Scholar 

  • Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. N Engl J Med 328: 176–183

    Article  Google Scholar 

  • Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 42: 747–755

    Article  Google Scholar 

  • Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 59: 1937–1943

    Article  Google Scholar 

  • Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566

    Article  Google Scholar 

  • Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO Study. Arch Neurol 62: 241–248

    Article  Google Scholar 

  • Rascol O, Brooks DJ, Melamed E (2005) for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954

    Article  PubMed  CAS  Google Scholar 

  • Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3: 362–368

    Article  PubMed  CAS  Google Scholar 

  • Shannon KM, Bennett JP Jr, Friedman JH (1997) Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 49: 724–728

    PubMed  CAS  Google Scholar 

  • Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P (2002) Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51: 604–612

    Article  PubMed  CAS  Google Scholar 

  • Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18: 1471–1473

    PubMed  CAS  Google Scholar 

  • Youdim MBH, Weinstock M (2001a) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(Npropargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate]. Cell Mol Neurobiol 21: 555–573

    Article  PubMed  CAS  Google Scholar 

  • Youdim MBH, Wadia A, Tatton W, Weinstock M (2001b) The antiparkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939: 450–458

    Article  PubMed  CAS  Google Scholar 

  • Youdim MD, Gross A, Finberg JP (2001c) Rasagiline [N-propargyl-1R(+)-aminoindaan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 1132: 500–506

    Article  PubMed  CAS  Google Scholar 

  • Youdim MBH, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M (2003) Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann N Y Acad Sci 993: 378–386

    Article  PubMed  CAS  Google Scholar 

  • Youdim MBH, Bar-Am O, Yogev-Falach M (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79: 172–179

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK

    Prof. A. H. V. Schapira

  2. Institute of Neurology, University College London, Queen Square, London, UK

    Prof. A. H. V. Schapira

  3. University Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, NW3 2PF, London

    Prof. A. H. V. Schapira

Authors
  1. Prof. A. H. V. Schapira
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute Alfred Fessard de Neurosciences, CNRS, Gif Yvette, France

    H. Parvez

  2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Würzburg, Germany

    P. Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag

About this chapter

Cite this chapter

Schapira, A.H.V. (2006). The use of rasagiline in Parkinson’s disease. In: Parvez, H., Riederer, P. (eds) Oxidative Stress and Neuroprotection. Journal of Neural Transmission. Supplementa, vol 71. Springer, Vienna. https://doi.org/10.1007/978-3-211-33328-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-33328-0_17

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-33327-3

  • Online ISBN: 978-3-211-33328-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation